Effect of Intermedin(1-53) on Angiotensin Ii-Induced Hypertrophy in Neonatal Rat Ventricular Myocytes

Jing-Hui Yang,Cun-Gen Ma,Yan Cai,Chun-Shui Pan,Jing Zhao,Chao-Shu Tang,Yong-Fen Qi
DOI: https://doi.org/10.1097/fjc.0b013e3181ddc785
IF: 3.271
2010-01-01
Journal of Cardiovascular Pharmacology
Abstract:Objectives: Intermedin (IMD) is coexpressed in the heart with its receptor, which suggests that it may have localized actions as a modulator of cardiac function. The present study was designed to observe the interaction between IMD and cardiac hypertrophy and the possible mechanism involved in the antihypertrophic effects of IMD1-53 in cultured neonatal ventricular myocytes.Methods: Myocyte hypertrophy was induced by treating the cells with angiotensin II, and the hypertrophic response was characterized by a significant increase in cell surface area, protein synthesis, and BNP mRNA expression.Results: Our results showed that angiotensin II led to an obvious decrease in the production, secretion, and mRNA expression of IMD and increase receptor activity modifying proteins 1, 3 mRNA expression. Moreover, IMD1-53 inhibited the angiotensin II-induced hypertrophic response and the effects of IMD1-53 were similar to those of equivalent-dose adrenomedullin and could been blocked by H89. Otherwise, in our study, IMD1-53 resulted in dose-dependent increases of cAMP production in cardiomyocytes.Conclusions: Thus, IMD and its receptor system are involved in cardiac hypertrophy, and like adrenomedullin, IMD1-53 exerts an antihypertrophic effect on neonatal cardiomyocytes and the effect can be mediated by the cAMP/PKA pathway.
What problem does this paper attempt to address?